- Home
- IMPP vs QNCX Comparison
IMPP vs QNCX Comparison
Compare IMPP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | QNCX |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.6M | 167.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMPP | QNCX |
|---|---|---|
| Price | $4.57 | $0.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $5.50 | ★ $10.00 |
| AVG Volume (30 Days) | 767.9K | ★ 33.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.55 | N/A |
| Revenue Next Year | $52.61 | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $0.09 |
| 52 Week High | $6.57 | $4.55 |
Technical Indicators
Market Signals| Indicator | IMPP | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 27.86 |
| Support Level | $4.11 | $0.09 |
| Resistance Level | $4.79 | $0.98 |
| Average True Range (ATR) | 0.31 | 0.01 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 63.68 | 18.57 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.